THIJS REYNIERS DEPARTMENT OF PUBLIC HEALTH, ITM

BREACH spring meeting 07/05/2022






Novel products ready for implementation



Long-Acting Injectable Cabotegravir ARV-based products in development (phase III)

Vaccines and antibodymediated prevention





Prematurely stopped in 2020: CAB-LA superior to TDF/FTC

1 Landovitz et al. NEJM, 2021 2 Delany-Moretlwe et al. Lancet, 2022








3224 cis-women²





Approved by US FDA 12/2021

1 Landovitz et al. NEJM, 2021 2 Delany-Moretlwe et al. Lancet, 2022








3224 cis-women²





7 considered as 'breakthrough infections'

1 Landovitz et al. NEJM, 2021 2 Landovitz et al. CROI, 2022








3224 cis-women²





2 Delany-Moretlwe et al. Lancet, 2022



Remaning questions for implementing CAB-LA

- Target population
- Acceptability



- Most optimal delivery sites and package
- Additional burden (8 instead of 12-weekly visits)
- Follow-up after 'injection phase'



- Feasibility (and cost) of sensitive HIV RNA assays
- Risk for drug resistance



Cost-effectiveness

Novel products ready for implementation




ARV-based products in development (phase III)

Vaccines and antibodymediated prevention



Monthly vaginal ring (dapivirine)







Novel products ready for implementation




Cabotegravir



ARV-based products in development (phase III) Vaccines and antibodymediated prevention



Other ARV-based HIV prevention products in development^{1,2}



1 PrEPWatch https://www.prepwatch.org/resource/developing-introducing-dpp/

2 Gilead - Company statement: Gilead and Merck announce temporary pause in enrollment for phase 2 study evaluating an oral weekly combination regimen of investigational islatravir and investigational-lenacapavir

Novel products ready for implementation



Cabotegravir



ARV-based products in development (phase III)



Vaccines and antibodymediated prevention



Preventive Vaccine

Long-Acting Iniectable Lenacapavir






uhambo A Journey of Hope to Prevent HIV	IMBOKODO	MOSAICO
Prime-boost vaccine against Clade C ¹	Adenovirus-26 based 'mosaic' vaccine ²	Also mosaic-approach against B, C and others ³
STOPPED 02/2020	STOPPED 08/2021	Results expected in 2023

1 Gray et al, NEJM, 2021

2 NIH - https://www.nih.gov/news-events/news-releases/hiv-vaccine-candidate-does-not-sufficiently-protect-women-against-hiv-infection 3 https://www.mosaicostudy.com/






Antibody-mediated prevention¹



Passive immunization by infusing broadly-neutralizing antibodies



1 Corey et al., NEJM, 2021



The future: more options!

Promising times for HIV prevention

■ More options → responding to different needs

Renewed energy for HIV prevention (e.g. oral PrEP)

Potential to further reduce the number of HIV infections

But... Wil it be enough?

- No silver bullet
- Maximise additional impact, rather than replace existing tools (e.g condom)
- How to reach 'the highest fruit'?





Thank you!



treyniers@itg.be